The estimated Net Worth of Marcio Souza is at least $9.5 Milion dollars as of 27 June 2023. Mr Souza owns over 10,000 units of Praxis Precision Medicines stock worth over $2,607,358 and over the last 7 years he sold PRAX stock worth over $5,449,753. In addition, he makes $1,440,799 as Pres a CEO & Director at Praxis Precision Medicines.
Sign up
Mr A PRAX stock SEC Form 4 insiders trading
Mr has made over 13 trades of the Praxis Precision Medicines stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of PRAX stock worth $10,600 on 27 June 2023.
The largest trade he's ever made was selling 102,945 units of Praxis Precision Medicines stock on 23 December 2019 worth over $5,034,011. On average, Mr trades about 9,846 units every 56 days since 2017. As of 27 June 2023 he still owns at least 45,001 units of Praxis Precision Medicines stock.
You can see the complete history of Mr Souza stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Marcio Souza M.B.A. biography
Marcio Souza M.B.A. is the Pres, CEO & Director at Praxis Precision Medicines.
What is the salary of Mr A?
As the Pres a CEO & Director of Praxis Precision Medicines, the total compensation of Mr A at Praxis Precision Medicines is $1,440,799. There are no executives at Praxis Precision Medicines getting paid more.
How old is Mr A?
Mr A is 42, he's been the Pres a CEO & Director of Praxis Precision Medicines since . There are 3 older and no younger executives at Praxis Precision Medicines. The oldest executive at Praxis Precision Medicines, Inc. is Dr. Bernard Ravina, 54, who is the Chief Medical Officer.
What's Mr A's mailing address?
Marcio's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Insiders trading at Praxis Precision Medicines
Over the last 4 years, insiders at Praxis Precision Medicines have traded over $16,246,895 worth of Praxis Precision Medicines stock and bought 242,294 units worth $603,092 . The most active insiders traders include Holdings A/S Novo, Parallel Master Fund L.P.Bl... a Dean J Mitchell. On average, Praxis Precision Medicines executives and independent directors trade stock every 48 days with the average trade being worth of $3,178,530. The most recent stock trade was executed by Jill De Simone on 5 October 2023, trading 14,500 units of PRAX stock currently worth $25,375.
What does Praxis Precision Medicines do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
What does Praxis Precision Medicines's logo look like?
Complete history of Mr Souza stock trades at Aeglea BioTherapeutics Inc, PTC Therapeutics Inc a Praxis Precision Medicines
Praxis Precision Medicines executives and stock owners
Praxis Precision Medicines executives and other stock owners filed with the SEC include:
-
Marcio Souza M.B.A.,
Pres, CEO & Director -
Dr. Bernard Ravina,
Chief Medical Officer -
Nicole Sweeny,
Chief Commercial Officer -
Alex Kane,
VP of Investor Relations & Corp. Communications -
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.,
Co-Founder & Chief Scientific Officer -
Karl Hansen,
Sr. VP of CMC -
Kelly McCue,
Chief People Officer -
Alex Nemiroff J.D.,
Gen. Counsel & Sec. -
Lauren Mastrocola,
VP of Fin. & Principal Accounting Officer -
Timothy Edwin Kelly,
CFO & Treasurer -
Dr. Steven Petrou,
Co-Founder & Chief Scientific Officer -
Dr. David B. Goldstein Ph.D.,
Co-Founder -
Stefan Vitorovic,
Director -
Jeffrey Chodakewitz,
Director -
Lifesciences Iii, L.P.Claru...,
-
Gregory Norden,
Director -
William D Young,
Director -
Dean J Mitchell,
Director -
Parallel Master Fund L.P.Bl...,
-
Jill De Simone,
Director -
Alex Nemiroff,
General Counsel and Secretary -
Nicole Sweeny,
Chief Commercial Officer -
Holdings A/S Novo,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Merit Ester Cudkowicz,
Director -
Lifesciences Iii, L.P.Claru...,
-
Timothy Edwin Kelly,
Chief Financial Officer -
Parallel Master Fund L.P.Bl...,
-
Marcio Souza,
Chief Executive Officer